These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 12721507)

  • 1. Somatostatin analogs in medical treatment of acromegaly.
    Racine MS; Barkan AL
    Endocrine; 2003 Apr; 20(3):271-8. PubMed ID: 12721507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical management of growth hormone-secreting pituitary adenomas.
    Racine MS; Barkan AL
    Pituitary; 2002; 5(2):67-76. PubMed ID: 12675503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological approach to the treatment of acromegaly.
    Ezzat S
    Neurosurg Focus; 2004 Apr; 16(4):E3. PubMed ID: 15191332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and tolerability of somatostatin analogs and other therapies for acromegaly.
    Burt MG; Ho KK
    Endocrine; 2003 Apr; 20(3):299-305. PubMed ID: 12721511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological therapy for acromegaly: a critical review.
    Muller AF; Van Der Lely AJ
    Drugs; 2004; 64(16):1817-38. PubMed ID: 15301564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of medical therapy in the management of acromegaly.
    Vance ML; Laws ER
    Neurosurgery; 2005 May; 56(5):877-85; discussion 877-85. PubMed ID: 15854234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
    Cozzi R; Attanasio R; Lodrini S; Lasio G
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New medical treatment for acromegaly.
    van der Lely AJ; de Herder WW; Lamberts SW
    Pituitary; 1999 Jun; 2(1):89-92. PubMed ID: 11081177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
    Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current management of acromegaly.
    Díez JJ; Iglesias P
    Expert Opin Pharmacother; 2000 Jul; 1(5):991-1006. PubMed ID: 11249504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.
    Selvarajah D; Webster J; Ross R; Newell-Price J
    Eur J Endocrinol; 2005 Apr; 152(4):569-74. PubMed ID: 15817912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
    Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs.
    Colao A; Pivonello R; Cappabianca P; Auriemma RS; De Martino MC; Ciccarelli A; de Divitiis E; Lombardi G
    J Endocrinol Invest; 2003; 26(10 Suppl):53-6. PubMed ID: 15497660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New perspectives in the medical treatment of acromegaly.
    Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G
    J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.